$8.76
8.75%
Nasdaq, Mon, Nov 25 2024
ISIN
US2537482067
Symbol
DFFN
Sector
Industry

Diffusion Pharmaceuticals Inc. Stock price

$8.76
-4.94 36.06% 1M
-9.93 53.13% 6M
+1.13 14.81% YTD
-1.02 10.43% 1Y
-19.90 69.43% 3Y
-26.49 75.15% 5Y
-35,203.74 99.98% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.84 8.75%
ISIN
US2537482067
Symbol
DFFN
Sector
Industry

Key metrics

Market capitalization $72.30m
Enterprise Value $25.64m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.55
P/S ratio (TTM) P/S ratio 7.18
P/B ratio (TTM) P/B ratio 1.58
Revenue growth (TTM) Revenue growth 559.46%
Revenue (TTM) Revenue $10.07m
EBIT (operating result TTM) EBIT $-13.47m
Free Cash Flow (TTM) Free Cash Flow $-11.02m
Cash position $46.66m
EPS (TTM) EPS $-1.64
P/E forward negative
P/S forward 8.68
EV/Sales forward 3.08
Short interest 0.12%
Show more

Is Diffusion Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Diffusion Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Diffusion Pharmaceuticals Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Diffusion Pharmaceuticals Inc. forecast:

Buy
100%

Financial data from Diffusion Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10 10
558% 558%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.97 8.97
10% 10%
89%
- Research and Development Expense 15 15
187% 187%
145%
-13 -13
0% 0%
-134%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
0% 0%
-134%
Net Profit -12 -12
47% 47%
-119%

In millions USD.

Don't miss a Thing! We will send you all news about Diffusion Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Diffusion Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of treatment for life threatening conditions. It offers Trans Sodium Crocetinate. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.

Head office United States
CEO John Alam
Employees 8
Founded 2001
Website www.cervomed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today